Cargando…

Quantification of [(18)F]afatinib using PET/CT in NSCLC patients: a feasibility study

INTRODUCTION: Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [(18)F]afatinib using positron emission tomography (PET) may identify those patients t...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Stadt, E. A., Yaqub, M., Lammertsma, A. A., Poot, A. J., Schober, P. R., Schuit, R. C., Smit, E. F., Bahce, I., Hendrikse, N. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431492/ https://www.ncbi.nlm.nih.gov/pubmed/32804306 http://dx.doi.org/10.1186/s13550-020-00684-4

Ejemplares similares

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
por: Van De Stadt, Eveline, et al.
Publicado: (2022)

Relationship between Biodistribution and Tracer Kinetics of (11)C-Erlotinib, (18)F-Afatinib and (11)C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients
por: van de Stadt, Eveline Annette, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
por: Bartelink, I. H., et al.
Publicado: (2022)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice
por: Slobbe, Paul, et al.
Publicado: (2015)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Quantification of O-(2-[(18)F]fluoroethyl)-L-tyrosine kinetics in glioma
por: Koopman, Thomas, et al.
Publicado: (2018)

Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Simulating the effect of cerebral blood flow changes on regional quantification of [(18)F]flutemetamol and [(18)F]florbetaben studies
por: Heeman, Fiona, et al.
Publicado: (2020)

In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [(18)F]DPA714 PET
por: Hagens, Marloes H. J., et al.
Publicado: (2018)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

Correction to: Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Harmonisation of PET/CT contrast recovery performance for brain studies
por: Verwer, E. E., et al.
Publicado: (2021)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
por: Kulkarni, Amit A, et al.
Publicado: (2022)

Optimized dual-time-window protocols for quantitative [(18)F]flutemetamol and [(18)F]florbetaben PET studies
por: Heeman, Fiona, et al.
Publicado: (2019)

Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
por: Hirsh, Vera
Publicado: (2015)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Impact of [(18)F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology
por: Cheebsumon, Patsuree, et al.
Publicado: (2011)

Feasibility of state of the art PET/CT systems performance harmonisation
por: Kaalep, Andres, et al.
Publicado: (2018)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems
por: Oprea-Lager, Daniela E., et al.
Publicado: (2015)

Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
por: Kolinger, Guilherme D., et al.
Publicado: (2019)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial
por: Bodar, Y. J. L., et al.
Publicado: (2020)

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients
por: Nappi, Antonio, et al.
Publicado: (2015)

Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology
por: Cheebsumon, Patsuree, et al.
Publicado: (2012)

Shortened duration whole body (18)F-FDG PET Patlak imaging on the Biograph Vision Quadra PET/CT using a population-averaged input function
por: van Sluis, Joyce, et al.
Publicado: (2022)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Altered GABA(A) receptor density and unaltered blood–brain barrier [(11)C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis
por: Froklage, Femke E, et al.
Publicado: (2015)

Assessment of different quantification metrics of [(18)F]-NaF PET/CT images of patients with abdominal aortic aneurysm
por: Akerele, Mercy I., et al.
Publicado: (2020)

Impact of (18)F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC
por: Al-Ibraheem, Akram, et al.
Publicado: (2021)

The value of head imaging after PET-CT staging in NSCLC
por: Kamil, A, et al.
Publicado: (2015)

Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
por: Köhler, Jens
Publicado: (2017)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u6435ecose1qg0c9426kg4fi1q